

# AHSR 2023 Conference Schedule



Activity	Location	Time
<b>Day One – Wednesday, October 18, 2023</b>		
<b><u>Registration</u></b>	Verizon Main Lobby	8:00-1:00 PM
<b><u>Pre-Conference Workshops</u></b> Addiction Health Services Research at NIH: Workshop for Early Career Investigators <i>(Tisha Wiley, PhD &amp; Laura Kwako, PhD)</i>  Using Population Claims Data for Substance Use Policy and Health Services Research <i>(Yuhua Bao, PhD &amp; Jake Morgan, PhD)</i>  Optimizing the Adaptation and Personalization of SUD Services: Innovations in Intervention and Experimental Designs <i>(Inbal Billie Nahum-Shani, PhD, Daniel Almirall, PhD, Susan A. Murphy, PhD, &amp; Linda M. Collins, PhD)</i>	Verizon 215  Verizon 225  Verizon 315	1:00-2:30 PM
<b><u>Break</u></b>	2 <sup>nd</sup> Floor Gallery / 3 <sup>rd</sup> Floor Gallery	2:30-3:00 PM
<b><u>Pre-Conference Workshops</u></b> Conducting Medicaid Related Research – Rationale, Priorities, Challenges, and Opportunities <i>(Maureen Stewart, PhD, Christina Andrews, PhD, Julie Donohue, PhD, Adam Stoler)</i>  Navigating the Myriad of Analytic Choices for Policy Evaluation Studies <i>(Megan Schuler, PhD, MS &amp; Beth Ann Griffin, PhD, SM)</i>  Leveraging Implementation Science in Your Research and in Your Career <i>(Mark McGovern, PhD, MA, Sara Becker, PhD, Cecelia Calhoun, MD, MPHS, MBA, H��l��ne Chokron Garneau, PhD, MPH, &amp; Lori Ducharme, PhD)</i>	Verizon 215  Verizon 225  Verizon 315	3:00-4:30 PM

Activity	Location	Time
<b>Break</b>	2 <sup>nd</sup> Floor Gallery / 3 <sup>rd</sup> Floor Gallery	4:30-5:00 PM
<b>Opening Reception and Poster Session One</b> <i>Complete list of poster presentations for this session can be found on pages 17-20.</i>	Verizon Main Lobby / Verizon 121	5:00-6:00 PM
<b>Day Two – Thursday, October 19, 2023</b>		
<b>Breakfast / Welcome</b> <ul style="list-style-type: none"> <li>Early Career Award Announcement at 7:30 AM</li> </ul>	Verizon Main Lobby	7:00-8:00 AM
<b>Poster Set-Up</b>	2 <sup>nd</sup> Floor Gallery / 3 <sup>rd</sup> Floor Gallery	7:00-10:45 AM
<b>Plenary One</b> Title: 15+ Years in the Making - When will the Digital Behavioral Health Revolution Deliver on its Promise? Speaker: Tanzeem Choudhury, PhD Affiliation: Cornell University	Verizon 121	8:00-9:00 AM
<b>Break</b>	Verizon Main Lobby / 2 <sup>nd</sup> Floor Gallery / 3 <sup>rd</sup> Floor Gallery	9:00-9:15 AM
<b>Scientific Break-Out Session</b>		9:15-10:30 AM

Activity	Location	Time
<p>Symposium 1 - Economic Analyses Within the HEAL Prevention Cooperative: Implementation Costs and Financing Considerations</p> <ul style="list-style-type: none"> <li>Investing in Interventions to Prevent Opioid Use Disorder in Adolescents and Young Adults: Start-Up Costs From NIDA's HEAL Prevention Initiative (<i>Margaret R. Kuklinski, PhD, MA</i>)</li> <li>Start-Up and Implementation Costs for the Trust Based Relational Intervention: Findings From NIDA's HEAL Prevention Initiative (<i>Diana Bowser, ScD, MPH</i>)</li> <li>Financing Substance Use Prevention in the United States in Healthcare, Justice, and Educational Settings (<i>Don Ekanayake, MS</i>)</li> <li>Police Assisted Diversion in Albany, NY: A Qualitative Evaluation of Facilitators and Barriers to Program Success (<i>Adam Vose-O'Neal, MA, LICSW, PhD candidate</i>)</li> </ul>	Verizon 215	9:15-10:30 AM
<p>Symposium 2 - Data-Driven Decision Making for Intervention Selection and Monitoring to Prevent Opioid Overdose Deaths, the HEALing Communities Study Case</p> <ul style="list-style-type: none"> <li>Data-Driven Decision Making to Prevent Opioid Overdose Deaths: Steps to Access, Visualize, and Engage Coalitions With Data to Inform Intervention Selection (<i>Peter Balvanz, MPH</i>)</li> <li>Engaging Community-Based Organizations and Community Coalition Members in Process Evaluation With Web-based Monitoring Reports (<i>Sarah Kosakowski, MPH</i>)</li> <li>Engaging an Urban Massachusetts Community in Data Walks to Understand Service Gaps and Opportunities to Prevent Opioid Overdose Deaths (<i>Jane Carpenter, MPH</i>)</li> <li>Engaging People With Lived Opioid Use Experience From Rural Massachusetts in Photovoice to Understand Factors Fueling the Local Opioid Epidemic (<i>Carolyn Damato-MacPherson, MPH</i>)</li> </ul>	Verizon 225	9:15-10:30 AM

Activity	Location	Time
<p>Symposium 3 - Mobile Health (mHealth) Interventions for Alcohol Use Disorder</p> <ul style="list-style-type: none"> <li>Adapting an mHealth Intervention for Alcohol Use Disorder Based on Stakeholder Feedback (<i>Qiang Xie, MEd</i>)</li> <li>A Mixed Methods Usability Test of a Digital Health App for Patients With Alcohol-Associated Liver Disease: Results of a Pilot Study (<i>Linda S. Park, PhD</i>)</li> <li>A Cost-Effectiveness Analysis of Telemedicine and Mobile Health Interventions to Support Continuing Care for Patients Receiving Treatment for Alcohol Use Disorder (<i>Xiang Li, MS</i>)</li> <li>Does Human Touch Improve an mHealth System for Alcohol-Related Harm-Reduction for Mild to Moderate Alcohol Use Disorder?: Study Design and Preliminary Results of a Three-Arm Randomized Clinical Trial (<i>Ming-Yuan Chih, PhD</i>)</li> </ul>	Verizon 315	9:15-10:30 AM
<p>Symposium 4 - Implementing Collaborative Care for Co-Occurring Disorders: Implementation Outcomes From Four Clinical Trials</p> <ul style="list-style-type: none"> <li>The CLARO Clinical Trial: Implementing Collaborative Care for Opioid Use Disorders With Co-Occurring Depression and/or PTSD in Low-Resource Settings (<i>Katherine E. Watkins, MD, MSHS</i>)</li> <li>The MICARE Study: Implementation Strategies, Opportunities, and Unique Challenges of an Encouragement Trial Approach (<i>Katharine Bradley, MD, MPH</i>)</li> <li>The Whole Health Study: Strategies for Implementation and Sustainment Success (<i>David Mandell, ScD</i>)</li> <li>Factors Affecting Implementation and Prescribing Medications for Opioid Use Disorder: A Community-based Systems Analysis (<i>Erin J. Stringfellow, PhD, MSW</i>)</li> </ul>	Verizon 121	9:15-10:30 AM
<p><b><u>Break</u></b></p>	Verizon Main Lobby / 2 <sup>nd</sup> Floor Gallery / 3 <sup>rd</sup> Floor Gallery	10:30-10:45 AM
<p><b><u>Scientific Break-Out Session</u></b></p>		10:45-12:00 PM

Activity	Location	Time
<p>Symposium 5 - Optimizing Multicomponent Interventions to Accomplish a Strategic Balance of Effectiveness and Ready Implementability: Latest Advances in the Multiphase Optimization Strategy</p> <ul style="list-style-type: none"> <li>• An Intervention Optimization Perspective on Building Multicomponent Interventions: Challenges, Opportunities, and Required Shifts in Thought (<i>Linda M. Collins, PhD</i>)</li> <li>• Applying Decision Analysis for Intervention Value Efficiency to Make Decisions About Candidate Intervention Components in the Multiphase Optimization Strategy: An Empirical Example From HIV Care (<i>Jillian Strayhorn, PhD</i>)</li> <li>• Decision Analysis for Intervention Value-Efficiency and Cost-Effectiveness Analysis of Multicomponent Interventions: Different Tools for Different Decisions (<i>David Vanness, PhD</i>)</li> <li>• Evaluating the Long-Term Population-Level Comparative Effectiveness of Buprenorphine/Naloxone Versus Methadone in British Columbia, Canada (<i>Benjamin Enns, MA</i>)</li> </ul>	Verizon 215	10:45-12:00 PM
<p>Symposium 6 - Results From the First NIH-Funded State-Based Analyses of Medical Marijuana Uptake</p> <ul style="list-style-type: none"> <li>• Statewide Assessment of Medical Marijuana Uptake and Healthcare Integration (<i>Joseph W. Thompson, MD, MPH</i>)</li> <li>• Who Qualifies for Medical Marijuana in Arkansas? Results From the First NIH-funded Population-level analysis of MMJ (<i>Teresa Hudson, PharmD, PhD</i>)</li> <li>• A Statewide Examination of Medical Marijuana Purchasing Patterns by Authorized Medical Condition (<i>Bradley C. Martin, PharmD, PhD</i>)</li> <li>• Impact of Medical Marijuana on Healthcare Utilization in PTSD Treatment (<i>Anthony Goudie, PhD</i>)</li> </ul>	Verizon 225	10:45-12:00 PM



Activity	Location	Time
<p>Symposium 9 - Maximizing Medicaid's Potential to Improve Access to Substance Use Disorder Treatment</p> <ul style="list-style-type: none"> <li>• Substance Use Disorder Treatment Regulatory Policy in State Contractual Agreements With Medicaid Managed Care Plans (<i>Rebecca Morris, MPP</i>)</li> <li>• State Coverage and Oversight Policies for Substance Use Disorder Treatment in Medicaid Managed Care (<i>Lauren Peterson, MPH, MA</i>)</li> <li>• Trends in State Medicaid FFS Benefits for Substance Use Treatment During the Opioid Crisis (<i>Amanda J. Abraham, PhD</i>)</li> <li>• Prior Authorization for Buprenorphine: The Role of Profit Status and Partisanship in Medicaid Managed Care (<i>Christina Andrews, PhD</i>)</li> </ul>	Verizon 215	2:00-3:15 PM
<p>Symposium 10 - Medications to Treat Opioid Use Disorder in Jail: Qualitative Findings on Implementation From the Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)</p> <ul style="list-style-type: none"> <li>• Top Leadership Perspectives and Experiences With Jail-Based MOUD treatment: Preliminary Qualitative Findings From County Sheriffs (<i>Claudia Santelices, PhD</i>)</li> <li>• Diversion of Medications to Treat Opioid Use Disorder: Reports From Formerly Incarcerated Adults in Massachusetts (<i>Elizabeth A. Evans, PhD, MA</i>)</li> <li>• Patient Perspectives of Jail-Based MOUD Treatment: Views of Individuals Who Have Returned to Community Following Incarceration (<i>Warren J. Ferguson, MD</i>)</li> <li>• Medications for Opioid Use Disorder (MOUD) Community Providers' Perspectives on Their Collaborations With Jails: A Qualitative Analysis (<i>Bianca Y. Planas-García</i>)</li> <li>• Extended-Release Buprenorphine: Qualitative Perceptions Among People Who Received Medication for Opioid Use Disorder in Jail (<i>Thomas J. Stopka, PhD, MHS</i>)</li> </ul>	Verizon 225	2:00-3:15 PM





Activity	Location	Time
<p>Oral Presentation 2 – Miscellaneous</p> <ul style="list-style-type: none"> <li>• Overview of Three Clinical Trials Within the Justice Community Opioid Innovation Network: Workgroup Approaches for Promoting Service Access Improvement (<i>Jennifer Becan, PhD</i>)</li> <li>• ROMPER: The RAND/USC OPTIC Method for Policy Expert Ratings (<i>Sean Grant, DPhil</i>)</li> <li>• Prescription Opioid Dose Reductions and Potential Adverse Events: A Multi-site Study in Eight U.S. Health Systems (<i>Verena E. Metz, PhD</i>)</li> <li>• Advancing Pharmacological Treatments for OUD: Outcomes of An Implementation Trial in Eight Veterans Health Administration Facilities (<i>Hildi J. Hagedorn, PhD</i>)</li> </ul>	Verizon 215	3:30-4:45 PM
<p>Oral Presentation 3 – COVID-19</p> <ul style="list-style-type: none"> <li>• Pediatric Opioid-Related Poisonings Before and During COVID-19 (<i>Shelby R. Steuart, PhD</i>)</li> <li>• "Would I Have Done That Without a Pandemic? Probably not": Perspectives of People Who Use Opioids and Prescribers on a Rapidly Developed Guidance Document for Prescribing Opioid Agonist Therapy in Ontario During the COVID-19 Pandemic (<i>Samantha Young, MD</i>)</li> <li>• What Can We Learn From COVID-19 to Improve Opioid Treatment? Expert Providers Respond (<i>Lesley Harris, MSW, PhD</i>)</li> <li>• Implementing Screening, Brief Intervention, and Referral to Treatment (SBIRT) for Risky Drug Use in FQHC Primary Care Clinics in the COVID-19 Era: The QUIT-Mobile Study (<i>Lillian Gelberg, MD, MSPH</i>)</li> </ul>	Verizon 225	3:30-4:45 PM
<p>Oral Presentation 4 – Costing</p> <ul style="list-style-type: none"> <li>• Micro-Costing the Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine With Referral for Opioid Use Disorder (<i>Danielle Ryan, MPH</i>)</li> <li>• Micro-Costing of CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (<i>Tyler Judge, MD candidate</i>)</li> <li>• Considerations and Strategies to Estimate the Total Costs of Implementing Medications for Opioid Use Disorder: A Pragmatic Micro-Costing Approach (<i>Hannah Cheng, MS</i>)</li> <li>• Implementation of the 988 Crisis Lifeline at the State-Level: Estimating Costs of Increased Call Demand at Lifeline Centers and Quantifying State Financing (<i>Jonathan Purtle, DrPH</i>)</li> </ul>	Verizon 315	3:30-4:45 PM

Activity	Location	Time
<p>Oral Presentation 5 – Social Support</p> <ul style="list-style-type: none"> <li>Peer Recovery Specialist-Delivered Behavioral Activation Intervention Shifting Substance Use Stigma (<i>Mary B. Kleinman, MS, MPH</i>)</li> <li>A Mixed-Methods Analysis of Community Factors Influencing Acceptance of Medication for Opioid Use Disorder Services (<i>Samuel Jaros</i>)</li> <li>Does Family Support Matter? The Impact of Support Person Attitudes Toward MOUD on Patient Perceptions of Support (<i>Jasmin Choi, MSW, MPH</i>)</li> <li>How Conflict, Cohesion, and Social Support Affect Patients in Buprenorphine Treatment and their Families (<i>Karen Chan Osilla, PhD</i>)</li> </ul>	Verizon 121	3:30-4:45 PM
<b>Break</b>	Verizon Main Lobby / 2 <sup>nd</sup> Floor Gallery / 3 <sup>rd</sup> Floor Gallery	4:45-5:00 PM
<p><b>Plenary Two</b></p> <p>Title: Leveraging Data to Understand and Guide Addiction Services Across New York State  Speaker: Chinazo Cunningham, MD, MS  Affiliation: Albert Einstein College of Medicine</p>	Verizon 121	5:00-6:00 PM
<b>Day Three – Friday, October 20, 2023</b>		
<b>Breakfast</b>	Main Lobby	7:00-8:00 AM
<p><b>Plenary Three</b></p> <p>Title: NIH Priorities for Addiction Health Services Research  Speakers: Laura Kwako, PhD and Carlos Blanco, MD, PhD, MS  Affiliation: NIH and NIDA</p>	Verizon 121	8:00-9:00 AM
<b>Break</b>	Verizon Main Lobby / 2 <sup>nd</sup> Floor Gallery / 3 <sup>rd</sup> Floor Gallery / Tata Main Lobby	9:00-9:15 AM

Activity	Location	Time
<p><b><u>Scientific Break-Out Session</u></b></p> <p>Oral Presentation 6 – Adolescent and Young Adults</p> <ul style="list-style-type: none"> <li>• Prolonged Exposure and Contingency Management for Posttraumatic Stress and Substance Use Disorders in Emerging Adults: Results of a Pilot Trial (<i>Kristyn Zajac, PhD</i>)</li> <li>• Disseminating Contingency Management for Adults and Adolescents With Substance Use Disorders Across Indiana (<i>Michael Smoker, PhD</i>)</li> <li>• Characteristics Associated With Impaired Driving and Risky Passenger Behaviors Among Adolescents in Driver Education (<i>Steven Tran, MS</i>)</li> <li>• Clinician Perspectives on Barriers and Facilitators to Providing Medications for Opioid Use Disorder for Adolescents in Indiana: A Qualitative Study (<i>Jayla French</i>)</li> </ul>	Verizon 215	9:15-10:30 AM
<p>Oral Presentation 7 – Policy</p> <ul style="list-style-type: none"> <li>• Impact of State Mandates of Naloxone Coprescription on Naloxone Prescription Dispensing in the United States (<i>Huiru Dong, PhD</i>)</li> <li>• Juvenile Probation Officers' Experiences Delivering Family-Based Contingency Management for Youth Substance Use: Task-Shifting to Increase Services in Rural Communities (<i>Tess K. Drazdowski, PhD</i>)</li> <li>• A Tale of Two Taxes: Comparing Perceptions of the Implementation of Policies Earmarking Taxes for Behavioral Health Services in California and Washington (<i>Jonathan Purtle, DrPH</i>)</li> <li>• Oregon Decriminalizes Drugs: Lessons From Local Implementation (<i>Danielle Good, PhD</i>)</li> </ul>	Verizon 225	9:15-10:30 AM
<p>Oral Presentation 8 – Methods/Modeling</p> <ul style="list-style-type: none"> <li>• Using System Dynamics Modeling to Study Temporal Trends in Opioid Overdose Response and Linkage to Medication for Opioid Use Disorder in Connecticut (<i>Rebekah Heckmann, MD, MPH, MPA</i>)</li> <li>• Using Dynamic Modeling to Simulate and Evaluate Evidence-Based Practices for Reducing Opioid Morbidity and Mortality Among Counties in New York State (<i>Nasim S. Sabounchi, PhD</i>)</li> <li>• An Agent-based Model of Opioid Use Disorder and the Impact of Intervention Strategies (<i>Praveen Kumar, PhD</i>)</li> <li>• Addressing Electronic Health Records (EHR) Discontinuity in Substance Use Disorder Research: The Synthetic Shrinkage Estimation (SSE) Approach (<i>Ali Jalali, PhD</i>)</li> </ul>	Verizon 315	9:15-10:30 AM

Activity	Location	Time
<p>Oral Presentation 9 – MOUD</p> <ul style="list-style-type: none"> <li>Leveraging Data Linkages to Investigate Health Insurance Instability and Mortality Among Patients Receiving Medications for Opioid Use Disorder (<i>Anh P. Nguyen</i>)</li> <li>Medication for Opioid Use Disorder and Risk of Overdose in the Year After Delivery (<i>Marian Jarlenski, PhD, MPH</i>)</li> <li>Retention and Critical Outcomes Among New Methadone Maintenance Patients Following Extended Take-Home Reforms (<i>Arthur Robin Williams, MD, MBE</i>)</li> <li>Organizational MOUD Adoption Lower Among Organizations Who Link Out to External Providers (<i>Rebecca E. Stewart, PhD</i>)</li> </ul>	Verizon 121	9:15-10:30 AM
<p>Oral Presentation 10 – Health Equity/Disparities</p> <ul style="list-style-type: none"> <li>The IMAT-PC-E: A Practical Measure of Health Equity in Addiction Medication Practice in Primary Care (<i>Hannah Cheng, MS</i>)</li> <li>The Role of Mandated Treatment on Expectant Mothers: A Propensity Score Approach (<i>Khadija Israel, LMSW</i>)</li> <li>Testing the Incremental Effectiveness of Pay-for-Performance to Improve Implementation of a Motivational Interviewing Brief Intervention for Substance Use Disorders in HIV Settings: Results of a Cluster-Randomized Type 3 Hybrid Trial (<i>Bryan R. Garner, PhD</i>)</li> </ul>	Tata 131	9:15-10:30 AM
<p>Oral Presentation 11 – Alcohol-Use</p> <ul style="list-style-type: none"> <li>Latino-White Disparities in Screening and Receipt of Medications for Unhealthy Alcohol Use in the OCHIN Network of Community Health Clinics (<i>Brian Chan, MD</i>)</li> <li>Reducing Alcohol Use Among Emerging Adults Experiencing Homelessness: 24-Month Outcomes From a Cluster Cross-Over Randomized Controlled Trial of AWARE (<i>Joan S. Tucker, PhD</i>)</li> <li>Spatial Associations Between Alcohol Detection in Opioid-Involved Overdose Deaths and Alcohol Outlets (<i>Adam Viera, PhD, MPH</i>)</li> <li>Emerging Adult Preferences for Receiving Brief Alcohol Interventions (<i>Jacob Tempchin, MS</i>)</li> </ul>	Tata 141	9:15-10:30 AM

Activity	Location	Time
<p>Oral Presentation 12 – Social Perceptions/Stigma</p> <ul style="list-style-type: none"> <li>• A Multidimensional, Socio-Ecological View of Access to Medications for Opioid Use Disorder: Associations of Access Among Persons Who Inject Drugs and the Rural Risk Environment (<i>Marynia Kolak, PhD</i>)</li> <li>• "I Would Do Anything But That": Attitudes Towards Sex Work Among Rural People Who Use Drugs (<i>Alex Rains</i>)</li> <li>• Siyakhana: A Stepped-Wedge Trial to Reduce Stigma Towards Substance Use Among Community Health Workers in TB/HIV Care in South Africa (<i>Kristen S. Regenauer, MS</i>)</li> <li>• Using Social Norms to Decrease Post-Surgical Opioid Prescribing: A Cluster Randomized Trial (<i>Katherine E. Watkins, MD, MSHS</i>)</li> </ul>	Tata 151	9:15-10:30 AM
<p><b><u>Break</u></b></p>	Verizon Main Lobby / 2 <sup>nd</sup> Floor Gallery / 3 <sup>rd</sup> Floor Gallery / Tata Main Lobby	10:30-10:45 AM
<p><b><u>Scientific Break-Out Session</u></b></p> <p>Oral Presentation 13 – Medicare</p> <ul style="list-style-type: none"> <li>• Early Experiences With Medicare's Reimbursement for Opioid Treatment Program Care, 2020-2022 (<i>Ateev Mehrotra, MD</i>)</li> <li>• Introduction of Medicare Coverage in Opioid Treatment Programs: Findings From the First Year (<i>Amanda J. Abraham, PhD</i>)</li> <li>• Prevalence and Association of Opioid Use Disorder Diagnosis With Nonpharmacologic, Nonopioid, and Opioid Pain Treatment Receipt Among Medicare Beneficiaries With Acute Low Back Pain (<i>Patience Moyo, PhD</i>)</li> <li>• Buprenorphine After Non-Fatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries (<i>Hillary Samples, PhD, MHS</i>)</li> </ul>	Verizon 215	10:45-12:00 PM

Activity	Location	Time
<p>Oral Presentation 14 – Medicaid</p> <ul style="list-style-type: none"> <li>• Use of Medicaid-Covered Peer Support Services in 2019 by Enrollees Diagnosed With Opioid Use Disorder Across 28 U.S. States (<i>Yuhua Bao, PhD</i>)</li> <li>• Association of Emergency Department Buprenorphine Receipt With Subsequent Treatment and Outcomes Among New Jersey Medicaid Beneficiaries (<i>Peter Treitler, PhD</i>)</li> <li>• Emergency Department-Based Peer Support for Opioid Overdose Survivors: Association of Program Participation With Drug Treatment Initiation and Outcomes (<i>Peter Treitler, PhD</i>)</li> <li>• Pilot Study of Screening, Treatment, and Referral for Substance Use Disorder in Medicaid Health Homes (<i>Olivia M. Hinds</i>)</li> </ul>	Verizon 225	10:45-12:00 PM
<p>Oral Presentation 15 – MOUD</p> <ul style="list-style-type: none"> <li>• Facilitators and Barriers to the Rapid Induction Procedure for Injectable Naltrexone in a Large, Multisite Inpatient Trial (<i>Kenzie Potter</i>)</li> <li>• Participant Reported Outcomes in Digitally-Provided Buprenorphine Treatment for Opioid Use Disorder Compared With Treatment as Usual Office-Based Treatment: An Observational Longitudinal Cohort Study (<i>Brian Chan, MD, MPH</i>)</li> <li>• Utilization of Medication for Opioid Use Disorder for Hospitalized Patients at 6 New York City Public Hospitals With an Addiction Consult Service (<i>Yasna Rostam-Abadi, MD, MPH</i>)</li> <li>• Barriers to Substance Use Disorder Treatment for Emergency Department Patients During COVID-19 (<i>Anjalee Sharma, PhD, MSW</i>)</li> </ul>	Verizon 315	10:45-12:00 PM
<p>Oral Presentation 16 – Health Equity/Disparities</p> <ul style="list-style-type: none"> <li>• Racial Disparities in the Implementation of the California Hub and Spoke System (<i>Diane Hilderbrand</i>)</li> <li>• Racial and Ethnic Disparities in the Receipt of Medications for Opioid Use Disorder Following Emergency Department Visits for Opioid Overdose in the Medicaid Population (<i>Thuy Nguyen, PhD</i>)</li> <li>• The Impact of CDC's Opioid Prescribing Guideline on Racial Disparities in Discontinuation of Opioid Treatment in the United States (<i>Huiru Dong, PhD</i>)</li> <li>• Disparities in Medication Initiation Among Females of Reproductive Age in Massachusetts With Opioid Use Disorder (<i>Rachel L. Epstein, MD, MSc</i>)</li> </ul>	Verizon 121	10:45-12:00 PM

Activity	Location	Time
<p>Oral Presentation 17 – Medical Providers</p> <ul style="list-style-type: none"> <li>Examining Barriers to Buprenorphine Treatment for OUD: X-Waiver Elimination and Increasing Support and Education for Providers (<i>Rebecca C. Bilden, MS</i>)</li> <li>Relaxing Buprenorphine X-Waiver Training Requirements Did Not Generally Increase Prescribers or Patients Receiving Treatment: Evidence From the Healing Communities Study (<i>Paul J Christine, MD, PhD</i>)</li> <li>R3 Supervisor Strategy in Substance Use Disorder Treatment Settings: A Qualitative Formative Evaluation of Provider Perceptions in Arkansas (<i>Jure Baloh, PhD, MHA</i>)</li> <li>Factors Associated With High Volume Buprenorphine Prescribers (<i>Bradley D. Stein, MD, PhD</i>)</li> </ul>	Tata 131	10:45-12:00 PM
<p>Oral Presentation 18 – State-Specific</p> <ul style="list-style-type: none"> <li>Receipt of Addiction Treatment After Non-Fatal Overdose and Risk of Subsequent Overdose: A Statewide Retrospective Cohort Study (<i>Benjamin A. Howell, MD</i>)</li> <li>Statewide Efforts to Address the Drug Overdose Crisis: Results from A Survey of Single State Agencies (<i>Miguel Antonio Estrada, MA</i>)</li> <li>A Spatiotemporal Analysis of the Association Between Residential Eviction and Fatal Overdose in Rhode Island (<i>Alexandra Skinner, MPH, PhD candidate</i>)</li> <li>Examining Changes in Program-Level Substance Use Disorder Treatment Outcomes in New York State (<i>Shazia Hussain</i>)</li> </ul>	Tata 141	10:45-12:00 PM
<p>Oral Presentation 19 – Harm Reduction</p> <ul style="list-style-type: none"> <li>Is There Fentanyl in the Stimulant Supply? Spatiotemporal Evidence From U.S. mortality Data (<i>Tse Yang Lim, PhD</i>)</li> <li>Knowledge is Power: Evaluating Community Drug Checking Services as a Tool to Combat British Columbia's Toxic Drug Crisis (<i>Kelvin Wu</i>)</li> <li>Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic Review (<i>Czarina N. Behrends, PhD, MPH</i>)</li> <li>Take-Home Naloxone for Prescription Opioid Patients: A Data-Driven Cost Effectiveness Analysis (<i>W. Alton Russell, PhD</i>)</li> </ul>	Tata 151	10:45-12:00 PM
<p><b>Poster Setup</b></p>	Verizon 121	12:00-1:00 PM

Activity	Location	Time
<b>Lunch</b>	Verizon Main Lobby	12:30-1:00 PM
<b>Poster Session Three</b> <i>Complete list of poster presentations for this session can be found on pages 25-27.</i>	Verizon 121	1:00-2:15 PM
<b>Conclusion of Conference</b>		2:15-3:00 PM



# AHSR 2023 Poster Session One

Poster Presentations #1-47 will be presented in Verizon 121.

Day One – Wednesday, October 18, 2023 (5:00-6:00 PM)			
#	Presenting Author	Affiliation	Poster Title
1	Ellerie Weber, PhD	Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai	Economic Burden of Opioid Use Disorder Among Pregnant and Postpartum People
2	Melissa N. Poulsen, PhD, MPH	Department of Population Health Sciences, Geisinger	Geographic Variation in Healthcare System Services, Comorbidities, Opioid Use, and Treatment Among Individuals With Opioid Use Disorder
3	Emily R. F. Beebe	Texas A&M University	Treatment Retention and Completion: An Examination of Predictors by Program Type
4	Erick G. Guerrero, PhD	Research to End Health Disparities Corp, I-Lead Institute	Testing the Role of Medicaid Expansion on Women’s Opioid Treatment Access and Engagement considering Organizational Capacity
5	Martha Tillson, PhD	University of Kentucky Center on Drug & Alcohol Research	Differences in Social Network Composition and Function Among Incarcerated Women With OUD by Participation in Jail-Based Substance Use Treatment
6	Christine Miranda-Diaz, PhD, MPHE	Universidad Central del Caribe	Culturally Responsive Training to Practitioners: Reducing Mental Health Disparities Among Hispanic and Latinos
7	Ignacio Bórquez, MA	Department of Population Health, New York University Grossman School of Medicine	What Determines Methadone Take-Home Patterns? A Sequence Analysis Comparing 6-Month Trajectories of Newly Admitted Patients at Opioid Treatment Programs (OTPs) Before and After COVID-19 Across 9 U.S. Sites
8	Matt Webster, PhD	Department of Behavioral Science, University of Kentucky	Perceived Substance Use Treatment Barriers Among Justice-Involved Women With Opioid Use Disorder
9	Evan J. Batty, MA	Department of Sociology, University of Kentucky	Recovery Capital as a Predictor of Medication for the Treatment of Opioid Use Disorder Utilization After Community Reentry Among Prison-Based Treatment Program Participants
10	Charlotte Merrick	Brown University School of Public Health	Administrator Perspectives on Post-Acute Care in Skilled Nursing Facilities for People With Opioid Use Disorder: A Qualitative Study
11	Michael Fendrich, PhD	Advocate Aurora Research Institute	Community-Based Substance Use Treatment Programs for Reentering Justice-Involved Adults: A Scoping Review
12	Tami Mark, PhD, MBA	RTI International	Needs and Gaps in Coverage of Opioid Use Disorder Treatment Among Medicare Beneficiaries
13	Adetayo Fawole, MD, MPH	Department of Population Health, New York University Grossman School of Medicine	Perceptions of Overdose Risk: A Qualitative Analysis of Persons Engaged in Polysubstance Use in New York City
14	Nina Mulia, DrPH	Alcohol Research Group, Public Health Institute	Racial, Ethnic and Insurance-Related Disparities in Alcohol Screening and Brief Intervention After U.S. Health Care Reform

15	Michael Campos, PhD	UCLA Gambling Studies Program, Semel Institute on Neuroscience and Human Behavior, David Geffen School of Medicine	Latino/a Treatment Seeking Gamblers in the California Gambling Education and Treatment Services (CalGETS) Program
16	Sugy Choi, PhD	Department of Population Health, New York University Grossman School of Medicine	Uncovering Disparities in Patient-Provider Encounters: Exploring Perspectives From Patients and Providers
17	Zainab S. Shah	Butler Hospital Behavioral Medicine and Addictions Research Department	Sex Differences in the Relationship Between Nicotine Dependence and Smoking Abstinence Self-Efficacy in Depressed Adults
18	Shashi Kapadia, MD, MS	Weill Cornell Medicine	Racial and Ethnic Disparities in Medication for Opioid Use Disorder Receipt Among Medicaid Enrollees Hospitalized With Infective Endocarditis
19	Ahmed M. Bayoumi, MD, MSc, FRCPC	MAP Centre for Urban Health Solutions and Department of Medicine, St. Michael's Hospital, Unity Health Toronto and Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto	Understanding Drug Criminalization: A Community-Based Group Model Building Approach to Prepare for Decriminalization
20	Lingshu Xue, PhD	Department of Health Policy and Management, School of Public Health, University of Pittsburgh	Using Machine Learning to Predict Opioid Use Disorder (OUD) Acute Care Use in the Pennsylvania Centers of Excellence Program
21	Mary A. Hatch, PhD	Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, University of Washington	Program Director Attitudes Toward Medication-Assisted Treatment for Opioid Use Disorder in Non-Traditional Settings
22	Ruijie Liu, PhD candidate	Department of Health Policy and Management, Yale School of Public Health	Expanding Coverage of Opioid Treatment Programs and Changes in Access to Opioid Use Disorder Treatment Services in Medicare
23	La Sonya A. Goode, MPH	RTI International	Unraveling Barriers to Alcohol Treatment: Leveraging Dimensions of Access to Address Subgroup Differences and Promote Equitable Health Outcomes
24	Carla J. Rash, PhD	Calhoun Cardiology Center, Departments of Medicine & Psychiatry, UConn Health School of Medicine,	Alternative 911 Emergency Response Teams: Hartford's HEARTeam Operations, Co-response Patterns, Safety, and Services Outcomes in the First Year
25	Techna Cadet, MS, PhD candidate	Department of Population Health Sciences, Weill Cornell Medicine	Determinants of Willingness to Pay for an Alcohol/Drug-Free Day Over Time, Among HIV+ Individuals Who Use Substances in South Africa
26	Sophia N. D. Negaro, LMSW	Arnold School of Public Health, University of South Carolina	Disparities in Geographic Distance to Substance Use Disorder Treatment Among Racial and Ethnic Groups in Rural Communities
27	Ji E. Chang, PhD	Department of Public Health Policy and Management, New York University School of Global Public Health	Substance Use Disorder Program Availability in Safety-Net and Non-Safety-Net Hospitals in the United States
28	Heather Fitzsimons, MPH	Department of Psychiatry, University of Maryland School of Medicine	Correlates of Staff Acceptability of a Novel Telemedicine Buprenorphine Program in a Rural Detention Center
29	Louise Durand	School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences	Prescription Drugs With Potential for Misuse in Irish Prisons: Analysis of National Prison Prescribing Trends, by Gender and History of Opioid Use Disorder, 2012 to 2020
30	Rachel L. Epstein, MD, MSc	Departments of Medicine and Pediatrics, Sections of Infectious Diseases, Boston University Chobanian and Avedisian School of Medicine	Perinatal Hepatitis C Virus Exposure: Trends in Incidence, Testing and Treatment in Massachusetts, 2014-2020

31	Berkeley Franz, PhD	Ohio University Heritage College of Osteopathic Medicine	Rural-Urban Disparities in the Availability of Hospital-Based Addiction Consult Services for Opioid Use Disorder
32	Michele Staton, PhD, MSW	Department of Behavioral Science, University of Kentucky	Substance Use Disorder Treatment and Traumatic Stress as Correlates of Relapse Following Release From Jail Among Women With Opioid Use Disorder
33	Allison Perry, MHS	Department of Population Health, NYU Grossman School of Medicine	Access and Disparities in Medication Treatment for Opioid Use Disorder Among Patients With Comorbid Opioid Use Disorder and Chronic Pain During the COVID-19 Pandemic
34	Zoe Lindenfeld	New York University School of Global Public Health	Comparing Rates of Undiagnosed Hypertension and Diabetes Among Individuals With and Without Substance Use Disorders
35	Megan F. Dickson, PhD	Department of Behavioral Science, University of Kentucky	Correlates of Substance Use Treatment Completion Among Rural Pregnant and Postpartum Women
36	Seungbin Oh, PhD	Department of Psychiatry, Boston University School of Medicine	Opioid Misuse and Comorbid Substance Use: Suicide Ideation and Suicide Attempts Among U.S. adolescents and Young Adults: Findings From 2015-2019 National Survey on Drug Use and Health (NSDUH)
37	Haofan Yang, MPH candidate	NYU School of Global Public Health	Understanding Substance Use Patterns and Co-Occurring Mental Health Disorders Among Asian American and Non-Hispanic White Populations
38	Leah L. Habersham, MD, MBA, MS	Department of Psychiatry, Department of Obstetrics, Gynecology & Reproductive Sciences, Icahn School of Medicine at Mount Sinai	Content Analysis of Maternal Toxicology Testing Policies to Inform Equity in Substance Use Disorder Identification
39	Uzma Ahmed, MSW, RSW	MAP Centre for Urban Health Solutions, St. Michael's Hospital, Unity Health Toronto	Regulations Over Relationships: Staff Experiences of Work, Grief and Loss in Supervised Consumption Sites During the COVID-19 Pandemic
40	Natrina L. Johnson, PhD candidate	Department of Health Law, Policy, and Management, Boston University School of Public Health	Similar Yet Dissimilar Experiences of Black and White Women and Men in Office-Based Addiction Treatment (OBAT)
41	Courtney R. Yarbrough, PhD	Department of Health Policy and Management, Rollins School of Public Health, Emory University	Use of Take-Home Methadone in Opioid Treatment Programs According to Local COVID-19 Severity and Opioid Treatment Program Characteristics
42	Erin M. Annunziato, MPH	Department of Epidemiology, Columbia University Mailman School of Public Health	Adolescent Substance Use Treatment Outcomes in the U.S. Between 2017-2020: Effects by Criminal Legal System Referral Source, Race, Ethnicity, and Sex
43	Derek Satre, PhD	Department of Psychiatry and Behavioral Sciences, University of California, San Francisco	Examining the Relationship of Unhealthy Alcohol Use, Polysubstance Use and Sociodemographic Factors to HIV Care Outcomes in an Integrated Healthcare System
44	Aeriell Armas, MS	Department of Clinical Psychology, Palo Alto University	Biopsychosocial Correlates of Intimate Partner Violence Among Pregnant and Parenting Women With Substance Use Disorders During the COVID-19 Pandemic
45	Deepika Rao, PhD, MS, BPharm	Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College	Staying Connected During COVID: Attitudes, Preferences, and Use of Telehealth Services by Pregnant and Parenting Women With Substance Use Disorders
46	Corey J. Hayes, PharmD, PhD, MPH	Department of Biomedical Informatics, College of Medicine, University of Arkansas and Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Healthcare System	Are Rates of Retention on Buprenorphine for Treatment of Opioid Use Disorder Improving Equitably Among Veterans of Differing Races and Ethnicities?

47	Karen Chan Osilla, PhD	Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine	A Randomized Pilot Test of a Group Telehealth Intervention for Support Persons Affected by Opioid Use Disorder
----	---------------------------	---	---

# AHSR 2023 Poster Session Two

Poster Presentations #1-26 will be presented in the 2<sup>nd</sup> Floor Gallery.

Poster Presentations #27-53 will be presented in the 3<sup>rd</sup> Floor Gallery.

## Day Two – Thursday, October 19, 2023 (12:00-1:45 PM)

#	Presenting Author	Affiliation	Poster Title
1	Kayne D. Mettert	University of Washington and Kaiser Permanente Washington Health Research Institute	Exploring Patient Experiences With Alcohol, Cannabis, and Other Substance-Use Screening in Primary Care: A Qualitative Study
2	Shannon Gwin Mitchell, PhD	Friends Research Institute	Factors Affecting the Perceived Acceptability and Feasibility of Delivering Medications for Opioid Use Disorder in Maryland County Jails
3	Nina Mulia, DrPH	Alcohol Research Group, Public Health Institute	Alcohol Treatment Utilization Patterns: Latent Class Analysis of Service Settings With Variation by Race and Ethnicity
4	Carrie Pettus, PhD, MSW	Wellbeing & Equity Innovations	Growing Capacity: Mentoring for Translation and Dissemination
5	Braeden Kelly, MPH	Addiction Policy Forum	Stakeholder Engagement and Tailored Dissemination: Increasing Impact Through Meaningful Communication
6	Amy Murphy, MPP	George Mason University Star School of Public Policy	Website Presentations That Glow: Engaging the Audience
7	Erika L. Crable, PhD, MPH	University of California, San Diego	Leadership and Organizational Change for Implementation-Systems Level (LOCI-SL) to Prepare for Systemwide Sustainment of Evidence-Based Substance Use Treatment
8	Miranda Greiner, MD, MPH	New York Psychiatric Institute Department of Psychiatry and Columbia University Medical Center, Division of Substance Use Disorders	Fentanyl and Buprenorphine Induction: Data from the CTN-0097/SWIFT Trial
9	Gabriela M. Rodríguez, PhD	Department of Psychiatry, Indiana University School of Medicine	Leveraging Administrative Data to Characterize Pathways to Behavioral Health Services for Youth Involved in the Juvenile Justice System in Rural Indiana
10	Allison Lin, MsC, MD	Department of Psychiatry, University of Michigan	Identifying, Reaching, and Engaging Primary Care Patients in Need of Alcohol Use Disorder Treatment: Early Data From a Remote Randomized Controlled Trial
11	Joseph E. Glass, PhD, MSW	Kaiser Permanente Washington Health Research Institute	An Effectiveness-Implementation Trial of a Care Navigation Intervention to Increase Initiation of Substance Use Disorder Treatment
12	James H. Ford II, PhD	Social and Administrative Sciences Division, School of Pharmacy, University of Wisconsin-Madison	A Comparative Implementation Trial: Stagewise Implementation-to-Target Medications for Addiction Treatment (SITT-MAT)

13	James H. Ford II, PhD	Social and Administrative Sciences Division, School of Pharmacy, University of Wisconsin-Madison	"Is this what we signed up for?" Organizational Participant Expectations For and Experiences After Joining an Implementation Study
14	Steven Belenko, PhD	Department of Criminal Justice, Temple University	Areas of Greatest Need and Prioritization Along the Substance Use Service Cascade: Goal Identification in Criminal Legal-Provider Systems
15	Aryn Z. Phillips, PhD, MPH	Department of Health Policy and Management, University of Maryland School of Public Health	Patterns of Health Care Interactions of Individuals With Alcohol Use Disorder: A Latent Class Analysis
16	Aryn Z. Phillips, PhD, MPH	Department of Health Policy and Management, University of Maryland School of Public Health	Decoupling of Screening & Referral to Treatment of Substance Use Disorders by U.S. Hospitals
17	Jennifer McNeely, MD, MS	Department of Population Health, NYU Grossman School of Medicine	Implementing EHR-Integrated Screening for Substance Use in Primary care: Approaches That Can Increase Feasibility and Effectiveness
18	Siara I Sitar	Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine	Substance Use Severity as a Predictor for Receiving Medication for Opioid Use Disorder Among Adolescents: An Analysis of the 2019 TEDS
19	Patricia Lincourt	New York Office of Addiction Services and Supports	Early Implementation of an Electronic Measurement-Based Care Tool for Substance Use Disorder Treatment: Lessons From the eTPA8
20	Katherine S. Elkington, PhD	Columbia University and the New York State Psychiatric Institute	Mixed-Methods Analysis of Shared and Differing Beliefs Related to Medications for Opioid Use Disorder Among Opioid Court Stakeholders: Moving Beyond Stigma
21	Jill Viglione, PhD	Department of Criminal Justice, University of Central Florida	Examination of the Stepping Up Initiative: Implementation Mechanisms and Outcomes to Improve Behavioral Health Services for Justice-Involved Individuals
22	Gerald Cochran, MSW, PhD	Department of Internal Medicine, University of Utah	Adaptation and Implementation of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool (PharmTool, CTN-0138)
23	Tennisha N. Riley, PhD	Department of Counseling and Educational Psychology, Indiana University	Investigating Cultural Competence Among Youth Substance Use Treatment Providers
24	Jeffrey Bratberg, PharmD, FAPhA	Department of Pharmacy Practice and Clinical Research, College of Pharmacy, University of Rhode Island	Secret Shopping: An Effective Post-Intervention Technique to Assess Real-World Naloxone and Nonprescription Syringe Access in Community Pharmacies
25	Allyson Dir, PhD	Indiana University School of Medicine	User-Centered Design of Data Visualizations to Improve Cross-System Collaboration and Youth Engagement in Substance Use Treatment
26	Emily Moner, MA	Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst	Designing Community-Based Post-Opioid Overdose Outreach Programs to Better Engage Vulnerable Populations in Rural Settings: Insights From People With Lived Experience
27	Lamia Y. Haque, MD, MPH	Department of Internal Medicine (Digestive Diseases) and Program in Addiction Medicine, Yale School of Medicine	Readiness to Provide Addiction Treatment in Hepatology Clinics: A Mixed-Methods Formative Evaluation
28	Joseph Silcox, MA	The Heller School for Social Policy and Management at Brandeis University	A Qualitative Review of Policy Landscape: Facilitators and Barriers to Pharmacy-Based Naloxone, Buprenorphine and Syringe Access Across Four-States

29	Madeline C. Frost, PhD, MPH	Department of Health Systems and Population Health, University of Washington School of Public Health	Implementation of Contingency Management for Substance Use Disorder Treatment in the Veterans Health Administration: A Cohort Study 2018-2022
30	Madeline C. Frost, PhD, MPH	Department of Health Systems and Population Health, University of Washington School of Public Health	Mixed-Method Evaluation of Alcohol-Related Care in Veterans Health Administration Hepatology Clinics Following Practice Facilitation
31	Morgan S. Anvari	Department of Psychology, University of Maryland, College Park	Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention (PRISM): Study Protocol
32	Margaret Lowenstein, MD, MPhil, MSHP	Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine	Interprofessional Perspectives on Caring for Hospitalized Patients With Opioid Use Disorder
33	Cynthia Nichols, MSW, LCSW	University of Connecticut School of Social Work	The Ethics of Involuntary Civil Commitments for Substance Use Disorders
34	Celine Villalba	Owens Institute for Behavioral Research, University of Georgia	Adaptations of Evidence-Based Practices in the Treatment of Cannabis Use Disorder Patients
35	Hannah K. Knudsen, PhD	Department of Behavioral Science, University of Kentucky	Naloxone Possession Among Rural and Urban Justice-Involved Individuals With a History of Opioid Use Disorder: Is There a Disparity?
36	Cathy J. Reback, PhD	Friends Research Institute	Getting Off: A Methamphetamine Treatment Mobile App for Men Who Have Sex With Men
37	Cathy J. Reback, PhD	Friends Research Institute	A Stepped Care Approach to Promote PrEP Initiation, Adherence and Persistence Among Trans Women and MSM With a Substance Use Disorder
38	Kerry Lindquist	Department of Global Research Talent, RAND Corporation	Navigating Funding Cliffs: An Exploration of the Dynamic Contextual Factors That Influence Evidence-Based Practice Sustainment
39	Danielle Rudes, PhD	Department of Criminal Justice & Criminology, Sam Houston State University	Screens & Ear Pods: Electronic Translation, Dissemination & Capacity Building for Broad Reach
40	Manesh Gopaldas, MD	Columbia University Irving Medical Center and New York State Psychiatric Institute	Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder: A Secondary Analysis
41	Thomas English, PhD	Culverhouse College of Business, University of Alabama	Evaluating SBIRT Outcomes in VA Primary Care Clinics
42	Andria B. Eisman, PhD, MPH	Department of Community Health, Division of Kinesiology, Health and Sport Studies, College of Education, Wayne State University	Making Implementation Costing More Accessible: An Implementation Costing Tool
43	Jennifer L. Brown, PhD	Department of Psychological Sciences, Purdue University	Project ASPIRE (Accelerating Substance use and Psychiatric screening Among Individuals at-risk or HIV-infected and facilitated Referral via the Emergency Department): Integration of Substance Use and Mental Health Screening With HIV Preventive Services in an Emergency Department
44	Pranav Padmanabhan	Department of General Internal Medicine, Professional Research Assistant, University of Colorado Anschutz Medical Campus	The Role of Data in Harm Reduction Outreach: Surveillance as a Barrier and Informal Networks of Information Sharing Among Grassroots Outreach Workers in Ohio
45	Mary Jo Larson, PhD	Institute for Behavioral Health, Brandeis University	Responding to Xylazine: Preparing Police Responders to Assist People Who Use Drugs With Xylazine

46	Mark Wolfson, PhD	Department of Social Medicine, Population, and Public Health, University of California, Riverside School of Medicine	Characterizing a National Network of Substance Misuse Prevention Technical Assistance and Training Providers
47	Dawn Goddard-Eckrich, EdD	Social Intervention Group, Columbia University School of Social Work	Characteristics of Drug-Involved Black Women Under Community Supervision; Implications for Retention in HIV Clinical Trials and Health care
48	Jill Eriksen, MBA	Mid-America Addiction Technology Transfer Center, Collaborative to Advance Health Services, University of Missouri - Kansas City	Mid-America Harm Reduction Technical Assistance Pilot Project
49	Cathy Long, PhD	MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital	The Multiple Makings of a Supervised Consumption Service in a Hospital Setting
50	Sharon Reif, PhD	Institute for Behavioral Health, Brandeis University	Brandeis-Harvard SPIRE Center: SUD Systems Performance Improvement Research and Engagement
51	Lillian Gelberg, MD, MSPH	Department of Family Medicine, David Geffen School of Medicine at UCLA	Cannabis Use Among Patients in Primary Care: Findings From a Screening Program Implemented in a Large Urban Health System
52	Megan Yerton, MD candidate	University of Washington School of Medicine	Potential Receipt of Behavioral and Pharmacologic Treatments by Patients With Methamphetamine Use Disorder in Rural-Serving Primary Care Clinics in the Pacific Northwest
53	Rebecca Arden Harris, MD MSc	Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania	Risk of Fatal Drug Overdose Among Middle-Aged Black Men: A Life Table Analysis



# AHSR 2023 Poster Session Three

Poster Presentations #1-43 will be presented in Verizon 121.

## Day Three – Friday, October 20, 2023 (1:00-2:15 PM)

#	Presenting Author	Affiliation	Poster Title
1	Casey R. Tak, PhD, MPH	Department of Pharmacotherapy, University of Utah College of Pharmacy	Evaluation of a Comprehensive Perinatal Substance Use Treatment Program: Impact on Access to and Satisfaction With Care Services
2	Emily Townsend Vinson, MPH	Department of Health Promotion and Behavior, College of Public Health, University of Georgia	So What Does Contribute to Alcohol Relapse? The Patient's Perspective on the Dynamic Model of Relapse's constructs
3	Haidong Lu, PhD	Department of Epidemiology of Microbial Diseases, Yale School of Public Health	Buprenorphine in Substance Use Disorder (SUD) Specialty Settings Versus Non-SUD Settings: Trial Emulation Using the Veterans Health Administration Data
4	Maureen Walton, PhD, MPH	Addiction Center, Department of Psychiatry, University of Michigan	Development of a Mobile Health Intervention for Emerging Adults With Regular Cannabis Use: A Pilot Micro-Randomized Trial
5	Drew Speer, DrPH	Substance Use Priority Research, University of Kentucky	A Cost Analysis of Peer Recovery Support Services: Addressing Critical Gaps in Opioid Use Disorder Treatment
6	Theresa E. Matson, PhD, MPH	Kaiser Permanente Washington Health Research Institute	Receipt of AUD Medications Among Primary Care Patients With an AUD Diagnosis in an Integrated Healthcare System With Routine Alcohol Screening and Assessment
7	Andrew Breck, PhD	Quantitative Sciences Department, Verily Life Sciences	Social and Economic Impact of Comprehensive Treatment For Opioid Use Disorder
8	Julie M. Donohue, PhD	Department of Health Policy and Management, University of Pittsburgh School of Public Health	Classifying Longitudinal Opioid Use Disorder Treatment Patterns Among Medicaid Enrollees Served by Centers of Excellence Using a Mixed Markov Model
9	Clarisa Wijaya, MA	Center for Dissemination and Implementation Science, Northwestern University Feinberg School of Medicine	Short and Sweet!: A Mixed Method Analysis of Parent Feedback on a Technology-Assisted Parenting Intervention for Adolescents in Residential Substance Use Treatment
10	Brittany Bass, PhD	Integrated Substance Abuse Programs, University of California, Los Angeles	Potency, Prices, and Product Variety in California's Licensed Cannabis Markets
11	Brittany Bass, PhD	Integrated Substance Abuse Programs, University of California, Los Angeles	Adult Use Cannabis Legalization, Cannabis Use Disorder Treatment, and Cannabis Use Disorder Treatment Outcomes in California, 2010-2020
12	Lewei (Allison) Lin MD, MS	Department of Psychiatry, University of Michigan Medical School and VA Ann Arbor Healthcare System	Care Utilization Among Patients With Stimulant Use Disorder During COVID-19: A National Cohort Study of U.S. Veterans
13	Sujaya Parthasarathy, PhD	Division of Research, Kaiser Permanente	A Cluster-randomized, Pragmatic Trial of Pharmacist-Delivered Primary Care Telemedicine Intervention for Alcohol Use Problems: Implementation Outcomes

14	Amanda Harris	Department of Epidemiology, University of North Carolina at Chapel Hill	Accessibility of Prescription Drug Monitoring Program (PDMP) Data for Research
15	Dhruv Khurana, PhD	University of California, Los Angeles	Detecting County and Regional Trends in Cannabis Use Disorder Prevalence Among Adult Medicaid Beneficiaries in California Using Claims Data
16	Minji Sohn, PhD	Ferris State University College of Pharmacy	Trends in Naloxone Dispensing From Retail Pharmacies in the United States During the COVID-19 Immediate Post-Emergency Period
17	Mary Brolin	Institute for Behavioral Health, Heller School for Social Policy and Management, Brandeis University	Insights on Implementation of the CCBHC Model for Integrated Care
18	Elisabeth Okrant, PhD, MPH	Institute for Behavioral Health, Brandeis University	Response to Addiction Recovery (R2AR): Pilot and Feasibility of a Patient-Reported Outcome Measure of Recovery
19	Cindy Parks Thomas PhD	Heller School for Social Policy and Management, Brandeis University	A Mixed Methods Study of Emergency Department Boarding of Patients With Substance Use Disorder
20	Randi Proffitt, PhD	Institute of Behavioral Research, Texas Christian University	Building and Implementing a Mobile Health Unit (MHU) in Partnership With a County Hospital Health System
21	Maureen T. Stewart, PhD	Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University	Substance Use Treatment Services in Medicaid Managed Care Plans: Covered Services and Utilization Management Requirements
22	Robert Bohler, MPH, MA, PhD	Heller School for Social Policy and Management, Brandeis University	Perceived Need for Treatment Among Adults With Alcohol and Cannabis Use Disorder: Implications for Closing the Treatment Gap
23	Joseph D. Perez	Department of Population Health Sciences, Weill Cornell Medicine	Costing the Incorporation of Low-Barrier Treatment of Opioid Use Disorder at a Syringe Service Program
24	Philip J. Jeng, MS	Department of Population Health Sciences, Weill Cornell Medicine	The Costs of Implementing and Sustaining an Opioid Use Disorder Collaborative Care Model in Primary Care Settings
25	Nicholas C. Jacobson, PhD	Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College	Using Passively Collected Sensor Data and Ecological Momentary Assessment With Deep Learning to Predict Non-Prescribed Opioid Use During Medication Treatment for Opioid Use Disorder
26	Stephen Orme, MA	Health Economics Program, RTI International	Cost of Abstinence-Contingent Wage Supplements for Adults Experiencing Homelessness and Alcohol Use Disorder
27	Kayla N. Tormohlen, PhD, MPH	Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health	Association of State laws That Require Co-Prescribing Opioids and Naloxone With Co-Prescribing Practices
28	Courtney D. Nordeck, PhD	Friends Research Institute	Treatment Retention Among Fentanyl-Exposed Patients: The Role of Patient Preferences for Fentanyl Over Other Opioids
29	Megan S. Schuler, PhD	RAND Corporation	Characterizing Heterogeneity in Opioid Markets Across the U.S.: A Latent Class Analysis
30	Rosalie Liccardo Pacula, PhD	University of Southern California Sol Price School of Public Policy	Using Policy and Innovation to Improve Life-Saving Access to Naloxone
31	Beth Ann Griffin, PhD	RAND Corporation	Association of State Policies and Trajectory of Buprenorphine Prescribers
32	Annie T. Chen, PhD	University of Washington School of Medicine	Leveraging Insights From Social Media to Develop Stigma Reduction Interventions

33	Lourah Kelly, PhD	University of Connecticut School of Medicine, Calhoun Cardiology	Contingency Management for Exercise Changes Within-Person Longitudinal Associations Among Drug Use Severity, Quality of Life, and Exercise
34	J. Travis Donahoe, PhD	Department of Health Policy and Management, University of Pittsburgh	Controlled Substances Enforcement and the Opioid Crisis
35	Sierra Castedo de Martell, PhD, MPH	JEAP Initiative and Lighthouse Institute, Chestnut Health Systems	Recovery Community Involvement in the Development of a Cost-Effectiveness Analysis and Calculator for Two Peer-Driven Interventions
36	Morgan Coombes, MSW and Shannon Goyette, MSW	Bridgewater State University School of Social Work	Incorporating Harm Reduction in Social Work Training and Practice: Challenges, Successes, and Ideas for Change at All Systems Levels
37	Alicia Lucksted, PhD	Department of Psychiatry, Division of Psychiatric Services Research, University of Maryland School of Medicine	Developing an Intervention to Enhance Stigma-Resistance Among People Using MOUD
38	Erminia Fardone, PhD	Department of Public Health Sciences, University of Miami Miller School of Medicine	Examining Poor Response to Substance Use Disorder Treatment: A Scoping Review
39	Dennis Watson, PhD	Chestnut Health Systems	Results From the POINT Pragmatic Trial: Assessment of a Peer-Based Emergency Department Intervention for People Who Use Opioids
40	Jabed Al Faysal, MS	Department of Pharmaceutical Outcomes and Policy, University of Florida	A Machine Learning Prediction of Buprenorphine Care Discontinuity Among Individuals With Opioid Use Disorder: Retrospective Observational Study
41	Mary Gray, PhD	Comagine Health	Providers Experiences Implementing the Oregon Medicaid Back Pain Policy Over Time: A Longitudinal Qualitative Study
42	Ruston Michael Koonce, PharmD	Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences	The Association Between Suspected Long-COVID and Stimulant Prescribing in the United States
43	Liz Friedman, MFA	GPS Group Peer Support LLC	Addressing Burnout and Retention of Addiction Treatment Workers Utilizing Group Peer Support Training Model

*This schedule was last updated on 10/13/2023.*